PhaseBio Pharma Becomes Medidata’s 1,000th Customer, Making Company First in Industry to Achieve This Milestone
May 17 2018 - 8:30AM
Business Wire
Innovative Biotech Company Adopts Medidata Rave
EDC, Benefiting From a Unified Platform for All Phases of the
Study
Biotech company, PhaseBio Pharmaceuticals, has become Medidata’s
(NASDAQ:MDSO) 1,000th customer. Medidata is the first and only
eClinical company to achieve this milestone. PhaseBio intends to
use the Medidata Clinical Cloud® for the initial Phase I study of
its newest clinical development program for treatment of an orphan
cardiopulmonary disease.
PhaseBio is a clinical-stage biopharmaceutical company committed
to developing improved biotherapeutics for the treatment of orphan
diseases, with an initial focus on cardiopulmonary indications.
Like many smaller, innovative life science companies, PhaseBio
chose to partner with Medidata due to its unified eClinical
platform, which drives better science and business through all
phases of a study.
“We have a very good understanding of our entire program
beginning with Phase I all the way through Phase III, and know
ahead of time that we plan to start as a single site in Phase I,
and rapidly expand as a global program,” said John Lee, chief
medical officer at PhaseBio. “Medidata Rave EDC has the capability
to scale with us, thanks to their robust data management platform,
which means that we would be able to monitor multiple studies in
parallel and potentially merge data sets as needed from these
studies in order to support a streamlined development plan leading
to approval when we arrive at that stage.”
Additional comments can be found in this video.
Founded in 1999, Medidata sets the industry standard as the
market leader in clinical trial technology. Built on a unified,
SaaS platform, Medidata has built a community of life science
leaders who are committed to leveraging their shared insights to
solve some of the biggest patient, regulatory, and quality
challenges in clinical development. Medidata's continued innovation
and ability to replace legacy systems is driven by:
A unified platform - Pharmaceutical companies, device
firms, and contract research organizations (CROs) of all sizes,
specializing across all therapeutic areas, are using the Medidata
Clinical Cloud. The global customer base includes 18 of the world's
top 25 global pharmaceutical companies and 18 of the top 25 medical
device companies.
Pioneering analytics and data - The Medidata Clinical
Cloud powers more than 14,000 studies involving more than 4 million
trial subjects, comprising more than 500,000 sponsor/site
relationships. Marrying the Medidata Enterprise Data Store (MEDS),
the largest clinical data repository, with advanced analytics
allows sponsors and CROs to collaborate and power cross-sponsor,
cross-study insights.
Unrivaled expertise - Medidata’s professional services
group ranked top in the industry in a recent Life Science Strategy
Group survey and the company’s 99% customer revenue retention rate
is proof positive of the added value Medidata provides as a partner
to its customers.
“This is a remarkable accomplishment for both Medidata and the
industry,” said Tarek Sherif, chairman and chief executive officer
at Medidata. “Our unified platform is driving the transformation of
clinical trials. It’s clear that applying advanced analytics and
artificial intelligence to valuable clinical data, empowers our
customers to make the best possible decisions to the benefit of
patients everywhere. We are proud that PhaseBio is our milestone
customer. They are a great example of how we help companies of all
sizes do better science and develop innovative therapies.”
About Medidata
Medidata's unified platform, pioneering analytics, and unrivaled
expertise power the development of new therapies for over 1,000
pharmaceutical companies, biotech, medical device firms, academic
medical centers and contract research organizations around the
world. The Medidata Clinical Cloud® connects patients, physicians
and life sciences professionals. Companies on the Medidata platform
are individually and collaboratively reinventing the way research
is done to create smarter, more precise treatments. For more
information: www.mdsol.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180517005112/en/
Medidata:Investor:Medidata SolutionsBetsy Frank,
+1 917-522-4620bfrank@mdsol.comorMedia:Medidata
SolutionsErik Snider, +1 646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024